A detailed history of Bank Of America Corp transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 375,393 shares of ALDX stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
375,393
Previous 378,490 0.82%
Holding current value
$1.79 Million
Previous $1.25 Million 61.58%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.19 - $6.32 $9,879 - $19,573
-3,097 Reduced 0.82%
375,393 $2.02 Million
Q2 2024

Aug 14, 2024

SELL
$3.25 - $4.72 $66,498 - $96,575
-20,461 Reduced 5.13%
378,490 $1.25 Million
Q1 2024

May 15, 2024

BUY
$2.77 - $4.22 $69,335 - $105,630
25,031 Added 6.69%
398,951 $1.3 Million
Q4 2023

Feb 14, 2024

BUY
$1.47 - $6.06 $113,547 - $468,092
77,243 Added 26.04%
373,920 $1.31 Million
Q2 2023

Aug 14, 2023

BUY
$7.11 - $11.89 $975,641 - $1.63 Million
137,221 Added 86.06%
296,677 $2.49 Million
Q1 2023

May 12, 2023

BUY
$5.77 - $9.93 $415,238 - $714,612
71,965 Added 82.25%
159,456 $1.58 Million
Q4 2022

Feb 10, 2023

SELL
$5.08 - $7.09 $96,596 - $134,816
-19,015 Reduced 17.85%
87,491 $608,000
Q3 2022

Nov 14, 2022

SELL
$3.8 - $7.74 $99,191 - $202,037
-26,103 Reduced 19.68%
106,506 $568,000
Q2 2022

Aug 12, 2022

BUY
$2.43 - $4.85 $100,397 - $200,382
41,316 Added 45.26%
132,609 $529,000
Q1 2022

May 16, 2022

SELL
$3.25 - $5.17 $791,687 - $1.26 Million
-243,596 Reduced 72.74%
91,293 $406,000
Q4 2021

Feb 08, 2022

BUY
$3.5 - $9.63 $846,422 - $2.33 Million
241,835 Added 259.89%
334,889 $1.34 Million
Q3 2021

Nov 15, 2021

SELL
$7.94 - $11.31 $41,375 - $58,936
-5,211 Reduced 5.3%
93,054 $818,000
Q2 2021

Sep 13, 2021

BUY
$10.44 - $14.85 $1.03 Million - $1.46 Million
98,265 New
98,265 $1.11 Million

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $278M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.